诺华公司Novartis AG (NVS) 2009年年度报告「NYSE」.pdf

1、 Novartis International AG Novartis Global CommunicationsCH-4002 Basel Switzerland http:/ 1 Core results for operating income,net income and earnings per share(EPS)eliminate the impact of acquisition-related factors and other significant exceptional items.See page 35 for further information.All prod

2、uct names appearing in italics are trademarks owned by or licensed to Novartis Group Companies.FINANCIAL REPORT RAPPORT FINANCIER FINANZBERICHT Novartis achieves record results in 2009 as momentum from recently launched products drives growth across its entire healthcare portfolio Novartis completes

3、 CEO succession process with appointment of Joe Jimenez as new CEO and simplified leadership organization Group delivers sustained business expansion and profit improvement with all divisions contributing to strong performance in 2009 o Net sales rise 11%in local currencies(lc)to USD 44.3 billion(+7

4、%in USD),as innovative products drive Pharmaceuticals to industry-leading growth and Vaccines and Diagnostics sells over 100 million influenza A(H1N1)pandemic vaccine doses o Core operating income grows 11%to USD 11.4 billion,as margin improves to 25.8%of net sales on business expansion and producti

5、vity gains o Core net income rises 8%to USD 10.3 billion,at a lower pace than core operating income mainly due to Alcon-related financing costs o Core EPS up 8%to USD 4.50 o Free cash flow before dividends advances 24%to USD 9.4 billion More than 30 drug approvals and full pipeline with 145 projects

6、 in pharmaceutical clinical development,of which 60 involve new molecular entities Forward productivity program exceeds savings goal by nearly 50%and a year ahead of schedule Access-to-medicine programs including medication for malaria and leprosy reach 80 million patients in 2009 with contributions